Abstract
Outcomes with long-acting injections (LAIs) are generally better than with oral antipsychotic therapy. However, the use of LAIs does not assure compliance with treatment and in clinical practice patients often miss injections or receive their injections later than intended. We conducted a case-control study to identify demographic and treatment associations with relapse (cases) on paliperidone 1-monthly injection (PP1M) compared with age-, gender-, and ethnicity-matched controls. We identified 16 cases and matched 43 controls. Baseline variables did not differ except that cases had received significantly more antipsychotic drugs before initiation with PP1M (3.94 vs. 2.12; p<0.001). Cases had fewer PP1M injections administered compared with the control group (9.69 vs. 11.37; p<0.001) and this group had a longer interval between injections than the control group (37 vs. 33days; p<0.001). Relapse on PP1M is associated with reduced frequency of injection and a longer interval between doses.
Highlights
In schizophrenia, there are strong links between poor adherence with oral antipsychotic therapy and relapse, admission, and increased NHS costs [1]
The use of long-acting injections (LAI) formulations significantly reduces relapse compared with oral treatment [3]
This study demonstrated an association between relapse and a lower number of paliperidone 1-monthly injection (PP1M) injections administered over a 12-month period
Summary
There are strong links between poor adherence with oral antipsychotic therapy and relapse, admission, and increased NHS costs [1]. The use of long-acting injections (LAI) formulations significantly reduces relapse compared with oral treatment [3]. Most mirror image studies show a clinically significant reduction in hospital admissions and bed days in the period after paliperidone LAI was initiated [4, 5]. This reduction in hospital use seems to be lost if injection frequency falls below a certain threshold [6]. We conducted a case–control study to identify demographic and treatment associations with relapse (cases) on paliperidone 1-monthly injection (PP1M) compared with age-, gender-, and ethnicity-matched controls. Relapse on PP1M is associated with reduced frequency of injection and a longer interval between doses
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European psychiatry : the journal of the Association of European Psychiatrists
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
